Anastrozole

• SPatial Heterogeneity of INtratumoral drug distribution Pending
  2025-520530-32-00 Phase IV 1 country Amsterdam UMC Stichting
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 Phase II 1 country Unicancer
• Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer. Pending
  2025-524208-31-00 Phase II 1 country Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 Phase III 7 countries Unicancer
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 Phase III 5 countries Unicancer
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting
  2024-515445-42-00 Phase III 15 countries Stemline Therapeutics Inc.
• Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Recruiting
  2025-522848-40-00 Phase IV 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trial Recruiting
  2023-506135-14-00 Phase III/IV 1 country Region Oerebro Laen
• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I… Recruiting
  2023-505758-17-00 Phase II 2 countries Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting
  2024-512360-55-00 Phase II 9 countries Medica Scientia Innovation Research S.L.
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread… Recruiting
  2024-511497-79-00 Phase II 2 countries Puma Biotechnology Inc.
• The RED FLASH study Recruiting
  2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting
  2023-508204-38-00 Phase III 9 countries Verastem Inc.
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting
  2023-505871-63-00 Phase III 13 countries Olema Pharmaceuticals Inc.
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting
  2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting
  2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting
  2022-500764-35-00 Phase IV 1 country Institut Für Frauengesundheit GmbH
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting
  2023-508094-88-00 Phase III 1 country University Of Florence
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting
  2024-512629-97-00 Phase II 1 country Centre Leon Berard
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG

Showing 1–24 of 45 trials